Abstract

Determination of interrelationships between impairments of laboratory parameters of immune and metabolic status in patients with chronic cerebral ischemia of I-II stages was carried out. The study included 104 patients, of which 76 were female and 28 males, with CCI on the background of II degree hypertension, of which 52 patients were with stage I and 52 with stage II at the age of 50 ± 5 years. Also, clinical and laboratory parameters were studied in 22 healthy donors of the same age. Evaluation of clinical and laboratory data was carried out at the beginning of treatment and 2 weeks after its end. The sorption capacity of erythrocytes and the sorption capacity of the glycocalyx (SEG), the activity of lipid peroxidation processes, the state of the antioxidant system were determined in blood plasma and erythrocytes, the level of stable metabolites of nitric oxide (SMNO), neopterin, C-reactive protein, cytokines (TNFα, IL- 1β, IL-8, IFNγ, IL-18, G-CSF, IL-4, IL-10), immunoglobulins (IgM, IgG, IgA), complement system components (C3, C4, C5, C5А), the phagocytic and oxygen-dependent activity of polymorphonuclear blood leukocytes. Comparative assessment of the results of correlation, factorial and cluster analyzes for assessing the parameters of the immune and metabolic status in patients with stage I CCI revealed the most significant laboratory parameters necessary for determination in the clinic for objective assessment of the severity of immune and metabolic disorders: TNFα, IL-8, IL-10, SMNO and NEG. In patients with CCI stage II, to objectively assess the severity of immune and metabolic disorders, TNFα, IL-8, IL-17, IL-10, the phagocytic number of neutrophils and SEG are recommended.

Highlights

  • In the world and in Russia, cerebrovascular disease (CEH), ranked second in the structure of mortality from circulatory diseases and total mortality, and the prevalence of chronic cerebral ischemia (CHEM) is 60-75% of all CEH

  • In patients with stage I, the most significant are at the systemic level – TNFα, IL-1β, IL-6, IL-8, IL-10, MDA, AGP, endothelin-1, C-reactive protein (CRP), stable metabolites of nitric oxide (SMNO), erythropoietin, and within red blood cells-MDA, AGP, superoxide dismutase (SOD), catalase, SMNO, sorption capacity of the glycocalyx (SEG), and CSE

  • In patients with stage II of the disease, according to factor analysis, the most significant indicators are the following in the blood – TNFα, IL-1β, IL-6, IL-8, IL-17, IL-18, IL-10, FH, AGP, SOD, endothelin-1, CRP, erythropoietin, inside red blood cells – MDA, AGP, SOD, SEG and CSE

Read more

Summary

Introduction

In the world and in Russia, cerebrovascular disease (CEH), ranked second in the structure of mortality from circulatory diseases and total mortality, and the prevalence of chronic cerebral ischemia (CHEM) is 60-75% of all CEH. The relationship between violations of laboratory indicators of immune and metabolic status in pa­ tients with stage I-II chronic brain ischemia during treatment was determined.

Results
Conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.